查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963865

解剖病理学溯源解决方案市场－全球产业规模、份额、趋势、机会、预测：按应用、最终用户、地区和竞争格局划分，2021-2031年

Anatomic Pathology Track & Trace Solution Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球解剖病理追踪解决方案市场预计将从 2025 年的 6.7393 亿美元成长到 2031 年的 10.3892 亿美元，复合年增长率为 7.48%。

这些解决方案包含整合的软硬体架构，旨在监控整个实验室工作流程中的生物检体，确保准确识别并维持严格的储存控制。市场成长的主要驱动力是全球慢性疾病发病率的上升（这些疾病需要进行组织诊断）以及消除威胁患者安全的分析前误差的迫切需求。此外，检查室认证的严格监管要求也迫使各机构采用这些自动化识别技术，以降低责任风险并提高营运效率。

市场概览
预测期 2027-2031
市场规模：2025年 6.7393亿美元
市场规模：2031年 1,038,920,000 美元
复合年增长率：2026-2031年 7.48%
成长最快的细分市场 医院检查室
最大的市场 北美洲

儘管存在这些市场驱动因素，但该市场仍面临许多障碍，例如实施所需的大量资金以及与现有诊断资讯基础设施整合的难度。诊断资源日益紧张，预算缩减，而效率提升却迫在眉睫，这些障碍因此而加剧。根据美国癌症协会预测，2024年美国将新增约2,001,140例癌症病例。诊断需求的激增凸显了建立强大追踪能力的迫切性，而经济挑战也使这一目标的实施变得更加复杂。

市场驱动因素

全球癌症和慢性疾病负担的日益加重是组织病理学领域采用可追溯性解决方案的主要驱动力，也因此对组织诊断的处理能力和准确性提出了更高的要求。随着肿瘤疾病发生率的上升，检查室面临巨大的压力，需要在保证准确性的前提下快速处理日益增多的切片检查检体。诊断需求的激增使得自动化可追溯性系统成为管理复杂工作流程并确保从检体采集到储存整个流程完整性的必要手段。美国癌症协会2025年1月发布的《2025年癌症事实与数据》报告强调了这种可扩展基础设施的必要性，该报告预测，仅在美国就将新增2,041,910例癌症病例。

同时，减少误诊和误认的重要性日益凸显，这促使检查室实施稳健的控制链技术，以确保病患安全。由于人工贴标和处理日益被视为高风险且不可持续，因此，利用条码和RFID技术的追踪系统正逐渐被采用，以避免责任风险并满足严格的品质标准。行业监管机构也强调了对安全的重视。在2025年3月发布的《ECRI 2025年十大病人安全问题》报告中，与癌症和重大血管事件相关的误诊被列为第七大挑战。此外，监管合规性也在推动这一趋势，美国病理学家协会（CAP）2025年3月的报告也印证了这一点。报告指出，2024年共有创纪录的657家检查室获得初步认证，显示各实验室对标准化和零错误操作的承诺正在不断加深。

市场挑战

在解剖病理学领域实施可追溯性解决方案需要大量的资金投入，这成为市场成长的主要障碍。检查室需要承担高昂的硬体和软体初始成本，而将这些现代化工具连接到现有实验室资讯系统所需的额外费用更加剧了这项挑战。对于预算有限、缺乏资源承担复杂整合网路基础设施升级和员工再培训相关成本的小规模独立机构而言，这种财务负担尤其沉重。

这些经济困境因外部财政限製而进一步加剧，这些限制减少了可用于技术进步的资金。当检查室面临收入下降时，它们往往被迫优先考虑眼前的营运成本，而非资本投资。据美国病理学家学会称，2024年联邦医疗保险（Medicare）医生报销方案的最终草案将病理实验室服务的整体支付额削减了约2%。报销额的减少直接阻碍了病理实验室集团获得自动化追踪系统预算的能力，儘管这些系统具有明显的营运优势，但却导致其应用被推迟。

市场趋势

追踪系统与数位病理工作流程的整合正迅速成为一种变革性趋势，推动市场从实体追踪转向全面的诊断资料管理。这种融合满足了将实体检体与数位对应物（例如全玻片影像 (WSI)）关联起来的日益增长的需求，确保即使在虚拟诊断领域也能维护储存链。随着远距离诊断和远端病理的普及，同步玻片和数位副本之间的识别资讯对于业务连续性至关重要。根据 Labcorp 于 2024 年 2 月发布的《2024 年实验室领导者报告》，约 33% 的实验室决策者已经开始实施或规划数位病理工作流程，而对能够弥合物理和数位落差的追踪解决方案的需求也在不断增长。

同时，与实验室资讯系统 (LIS) 和电子健康记录 (EHR) 的无缝互通性已成为一项关键的市场需求，这要求的是深度双向资料集成，而非简单的连接。检查室正在摒弃那些造成数据孤岛的独立追踪解决方案，转而采用能够自动填充整个企业 IT 环境中的存取数据并即时更新病例状态的系统。这一趋势的驱动力在于消除冗余资料输入的需求，以及临床医生能够即时获取检体位置资讯的需求。医学实验室观察家 (Medical Laboratory Observer) 于 2024 年 4 月进行的「2024 年产业趋势调查」凸显了这项挑战的迫切性。调查发现，51% 的实验室专业人员认为互通性和资料整合的挑战是重大障碍，这影响了市场对开放式架构追踪平台的偏好。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球解剖学和病理学溯源解决方案市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按应用（载玻片追踪、检体追踪、组织盒/组织块追踪）
    • 依最终用户（医院检查室、独立/参考实验室、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美解剖病理学溯源解决方案市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲解剖病理追踪溯源解决方案市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区解剖病理学溯源解决方案市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲解剖病理追踪溯源解决方案市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲解剖病理学溯源解决方案市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球解剖病理学溯源解决方案市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Leica Biosystems Nussloch GmbH
  • Thermo Fisher Scientific Inc
  • Zebra Technologies Corp.
  • Agilent Technologies Inc
  • CompuGroup Medical
  • LigoLab Information Systems
  • General Data Healthcare Inc.
  • Psyche Systems Corporation
  • Siemens Healthineers AG
  • Indica Labs, LLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 19182

The Global Anatomic Pathology Track & Trace Solution Market is projected to expand from USD 673.93 Million in 2025 to USD 1038.92 Million by 2031, registering a CAGR of 7.48%. These solutions comprise integrated hardware and software architectures designed to monitor biological specimens throughout the entire laboratory workflow, guaranteeing precise identification and maintaining a strict chain of custody. The market's growth is primarily driven by the rising global incidence of chronic diseases that demand tissue diagnostics and the imperative need to eliminate pre-analytical errors that endanger patient safety. Additionally, rigorous regulatory requirements for laboratory accreditation are compelling facilities to adopt these automated identification technologies to lower liability risks and enhance operational efficiency.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 673.93 MIllion
Market Size 2031USD 1038.92 MIllion
CAGR 2026-20317.48%
Fastest Growing SegmentHospital Laboratories
Largest MarketNorth America

Despite these positive drivers, the market faces obstacles due to the substantial capital required for implementation and the difficulties involved in integrating these systems with existing laboratory information infrastructures. This barrier is further exacerbated by the increasing strain on diagnostic resources, which demands higher efficiency while simultaneously tightening financial budgets. According to the American Cancer Society, approximately 2,001,140 new cancer cases were projected to occur in the United States in 2024. This escalating volume of diagnostic demand highlights the urgent necessity for robust tracking capabilities, even as economic challenges complicate their acquisition.

Market Driver

The rising global burden of cancer and chronic diseases serves as a major catalyst for the implementation of anatomic pathology track and trace solutions, creating a fundamental need for greater throughput and precision in tissue diagnostics. As oncological conditions become more prevalent, laboratories are under immense pressure to process growing volumes of biopsy specimens rapidly without sacrificing accuracy. This surge in diagnostic demand necessitates automated tracking systems to oversee complex workflows and guarantee specimen integrity from the point of collection to archiving. Highlighting this need for scalable infrastructure, the American Cancer Society's 'Cancer Facts & Figures 2025' report, released in January 2025, estimates that 2,041,910 new cancer cases will be diagnosed in the United States alone.

Simultaneously, the imperative to reduce diagnostic errors and misidentification acts as a powerful driver, pushing laboratories to adopt robust chain-of-custody technologies to ensure patient safety. Because manual labeling and handling are increasingly seen as risky and untenable, there is a distinct shift toward barcode and RFID-enabled tracking to mitigate liability and meet strict quality standards. This emphasis on safety is underscored by industry monitors; in March 2025, ECRI's 'Top 10 Patient Safety Concerns 2025' report listed diagnostic errors related to cancers and major vascular events as the seventh most critical challenge. Furthermore, regulatory compliance strengthens this trend, illustrated by the College of American Pathologists' March 2025 report, which noted that a record 657 laboratories achieved initial accreditation in 2024, signaling a deepening commitment to standardized, error-free operations.

Market Challenge

The significant capital investment needed to deploy anatomic pathology track and trace solutions represents a major hurdle to market growth. Laboratories must contend with high upfront costs for essential hardware and software, a challenge that is further complicated by the expense of interfacing these modern tools with legacy laboratory information systems. This financial strain is particularly acute for smaller, independent facilities that operate with limited budgets and lack the resources to easily absorb the costs associated with infrastructure upgrades or staff retraining for complex integrated networks.

These economic difficulties are intensified by external financial constraints that restrict the funds available for technological enhancements. When laboratories face diminished revenue streams, they are often compelled to prioritize immediate operational costs over capital equipment investments. According to the College of American Pathologists, the final Medicare Physician Fee Schedule in 2024 led to an overall payment reduction of approximately 2 percent for pathology services. This contraction in reimbursement directly hampers the ability of pathology groups to budget for automated tracking systems, delaying their adoption despite the evident operational advantages.

Market Trends

The convergence of track and trace systems with digital pathology workflows is rapidly becoming a transformative trend, evolving the market from physical tracking to comprehensive diagnostic data management. This integration addresses the increasing need to link physical specimens with their digital counterparts, such as whole slide images (WSI), ensuring the chain of custody persists into the virtual diagnostic realm. As remote sign-out and telepathology gain traction, maintaining synchronized identification between glass slides and their digital twins is essential for operational continuity. According to Labcorp's '2024 Lab Leader Report' from February 2024, approximately 33% of laboratory decision-makers have initiated or planned digital pathology workflows, driving a parallel demand for tracking solutions that bridge the physical-digital divide.

Concurrently, seamless interoperability with Laboratory Information Systems (LIS) and Electronic Health Records (EHR) has become a primary market requirement, necessitating deep, bi-directional data integration rather than simple connectivity. Laboratories are moving away from standalone tracking solutions that generate data silos, preferring systems that automatically populate accession data and update case status in real-time across the enterprise IT landscape. This trend is motivated by the need to eliminate redundant data entry and ensure specimen location data is instantly available to clinicians. The urgency of this issue is highlighted by the '2024 State of the Industry Survey' from Medical Laboratory Observer in April 2024, where 51% of laboratory professionals cited interoperability and data integration challenges as significant hurdles, thereby influencing the market's preference for open-architecture tracking platforms.

Key Market Players

  • Leica Biosystems Nussloch GmbH
  • Thermo Fisher Scientific Inc
  • Zebra Technologies Corp.
  • Agilent Technologies Inc
  • CompuGroup Medical
  • LigoLab Information Systems
  • General Data Healthcare Inc.
  • Psyche Systems Corporation
  • Siemens Healthineers AG
  • Indica Labs, LLC

Report Scope

In this report, the Global Anatomic Pathology Track & Trace Solution Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anatomic Pathology Track & Trace Solution Market, By Application

  • Slides Tracking
  • Specimen Tracking
  • Tissue Cassettes & Blocks Tracking

Anatomic Pathology Track & Trace Solution Market, By End User

  • Hospital Laboratories
  • Independent & Reference Laboratories
  • Others

Anatomic Pathology Track & Trace Solution Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anatomic Pathology Track & Trace Solution Market.

Available Customizations:

Global Anatomic Pathology Track & Trace Solution Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anatomic Pathology Track & Trace Solution Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Slides Tracking, Specimen Tracking, Tissue Cassettes & Blocks Tracking)
    • 5.2.2. By End User (Hospital Laboratories, Independent & Reference Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Anatomic Pathology Track & Trace Solution Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Anatomic Pathology Track & Trace Solution Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Anatomic Pathology Track & Trace Solution Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Anatomic Pathology Track & Trace Solution Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End User

7. Europe Anatomic Pathology Track & Trace Solution Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Anatomic Pathology Track & Trace Solution Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End User
    • 7.3.2. France Anatomic Pathology Track & Trace Solution Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Anatomic Pathology Track & Trace Solution Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Anatomic Pathology Track & Trace Solution Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Anatomic Pathology Track & Trace Solution Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End User

8. Asia Pacific Anatomic Pathology Track & Trace Solution Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Anatomic Pathology Track & Trace Solution Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End User
    • 8.3.2. India Anatomic Pathology Track & Trace Solution Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Anatomic Pathology Track & Trace Solution Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Anatomic Pathology Track & Trace Solution Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Anatomic Pathology Track & Trace Solution Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End User

9. Middle East & Africa Anatomic Pathology Track & Trace Solution Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Anatomic Pathology Track & Trace Solution Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Anatomic Pathology Track & Trace Solution Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Anatomic Pathology Track & Trace Solution Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End User

10. South America Anatomic Pathology Track & Trace Solution Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anatomic Pathology Track & Trace Solution Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Anatomic Pathology Track & Trace Solution Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Anatomic Pathology Track & Trace Solution Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Anatomic Pathology Track & Trace Solution Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Leica Biosystems Nussloch GmbH
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc
  • 15.3. Zebra Technologies Corp.
  • 15.4. Agilent Technologies Inc
  • 15.5. CompuGroup Medical
  • 15.6. LigoLab Information Systems
  • 15.7. General Data Healthcare Inc.
  • 15.8. Psyche Systems Corporation
  • 15.9. Siemens Healthineers AG
  • 15.10. Indica Labs, LLC

16. Strategic Recommendations

17. About Us & Disclaimer